Fermented infant formula (with Bifidobacterium breve C50 and Streptococcus thermophilus O65) with prebiotic oligosaccharides is safe and modulates the gut microbiota towards a microbiota closer to that of breastfed infants

Ферментированная смесь для грудных детей (с Bifidobacterium breve C50 и Streptococcus thermophilus O65) с пребиотическими олигосахаридами безопасна и модифицирует кишечную микробиоту, приближая ее к микробиоте детей, находящихся на грудном вскармливании
Jan Knol, Dominique Turck, Laurent Béghin, Sebastian Tims, Mieke Roelofs, Carole Rougé, Raish Oozeer, Thameur Rakza, G Chirico, Guus Roeselers, Jean‐Christophe Rozé
2020-07-23

Bifidobacterium breve C50fermented infant formulagut microbiota modulationprebiotic oligosaccharidessecretory IgA
BACKGROUND & AIMS: Microbiome-modulators can help positively steer early-life microbiota development but their effects on microbiome functionality and associated safety and tolerance need to be demonstrated. We investigated the microbiome impact of a new combination of bioactive compounds, produced by the food-grade microorganisms Bifidobacterium breve C50 and Streptococcus thermophilus ST065 during a fermentation process, and prebiotics in an infant formula. Tolerance and safety were also assessed. METHODS: An exploratory prospective, randomized, double-blind, controlled, multi-centre study was designed to investigate the effect of bioactive compounds and prebiotics (short-chain galacto-oligosaccharides (scGOS)/long-chain fructo-oligosaccharides (lcFOS) 9:1). Experimental formulas containing these bioactive compounds and prebiotics (FERM/scGOS/lcFOS), prebiotics (scGOS/lcFOS), or bioactive compounds (FERM), were compared to a standard cow's milk-based control formula (Control). Exclusively breastfed infants were included as a reference arm since exclusive breastfeeding is considered as the optimal feeding for infants. The study lasted six months and included visits to health care professionals at baseline, two, four and six months of age. Stool SIgA concentration was the primary study outcome parameter. RESULTS: There were 280 infants randomized over the experimental arms and 70 infants entered the breastfed-reference arm. Demographics were balanced, growth and tolerance parameters were according to expectation and adverse events were limited. At four months of age the median SIgA concentration in the FERM/scGOS/lcFOS group was significantly higher compared to the Control group (p = 0.03) and was more similar to the concentrations found in the breastfed-reference group. Bifidobacterium increased over time in all groups. The FERM/scGOS/lcFOS combination resulted in a microbiota composition and metabolic activity closer to the breastfed infants' microbiome. CONCLUSION: The FERM/scGOS/lcFOS combination showed a significant positive effect on SIgA levels. All formulas tested were associated with normal growth and were well-tolerated. Additionally, at four months of age the FERM/scGOS/lcFOS formula brought the microbiome composition and metabolic activity closer towards that of breastfed infants. CLINICAL TRIAL REGISTRY: Registration number NTR2726 (Netherlands Trial Register; www.trialregister.nl/).
1
A fermented infant formula containing compounds produced by Bifidobacterium breve C50 and Streptococcus thermophilus ST065 plus scGOS/lcFOS prebiotics was evaluated in a six-month randomized, double-blind, controlled multicenter study.
2
At four months, the fermented formula with scGOS/lcFOS produced significantly higher median stool SIgA than the control formula (p = 0.03), with values more similar to breastfed infants.
3
Bifidobacterium abundance increased over time across all formula and breastfed-reference groups.
4
Growth, tolerance, and adverse-event profiles were as expected, supporting the safety of the experimental formulas in the studied infants.
5
The fermented formula combined with scGOS/lcFOS shifted microbiota composition and metabolic activity closer to those observed in exclusively breastfed infants.

Fermented infant formula containing bioactive compounds from Bifidobacterium breve C50 and Streptococcus thermophilus ST065 combined with prebiotic oligosaccharides (scGOS/lcFOS)

Safety, tolerance, and modulation of gut microbiota composition, metabolic activity, and stool SIgA toward profiles closer to those of breastfed infants

Publication Details
Publication Date
2020-07-23
Journal
Publisher
ISSN
Cited by
69
Access Type
Author Information
Authors
Jan Knol
Dominique Turck
Laurent Béghin
Sebastian Tims
Mieke Roelofs
Carole Rougé
Raish Oozeer
Thameur Rakza
G Chirico
Guus Roeselers
Jean‐Christophe Rozé
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%